SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Lupus
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Fritzler, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fritzler, M. J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Drugs Recently Associated With Lupus Syndromes

Marvin J. Fritzler

Faculty of Medicine, The University of Calgary, 3330 Hospital Dr. NW, Calgary, AB Canada T2N 4N1

A number of drugs have recently been implicated in a syndrome that resembles systemic lupus erythematosus. One of the difficulties in many of these patients is that the signs, symptoms and serological abnormalities reported in these patients may be a natural consequence of the primary diseases rather than the incriminated drug. A second problem with the studies is a lack of unifom reporting of the techniques used to detect autoantibodies. For example, a patient that has a highly positive ANA with a homogeneous pattern of staining or a positive LE cell test usually has antibodies directed against chromatin components (DNA, histones, high mobility group (HMG) proteins). The discrepancies in clinical criteria and the serological techniques in many of these reports, emphasize the importance of using guidelines for the diagnosis of drug-induced or drug-related lupus. In the future, it appears that the increased use of biological response modifiers such as interferon-{alpha} and other cytokines may prompt more reports of lupus syndromes associated with their use.

Key Words: Drug-related lupus • Drug-induced lupus • Autoimmunity • Autoantibodies

Lupus, Vol. 3, No. 6, 455-459 (1994)
DOI: 10.1177/096120339400300605


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
LupusHome page
S. Paradela, W. Martinez-Gomez, B. Fernandez-Jorge, I. Castineiras, T. Yebra-Pimentel, P. Llinares, and E. Fonseca Capdevila
Toxic epidermal necrolysis-like acute cutaneous lupus erythematosus
Lupus, September 1, 2007; 16(9): 741 - 745.
[Abstract] [PDF]


Home page
LupusHome page
C.A.A. Silva and H.I. Brunner
Review: Gonadal functioning and preservation of reproductive fitness with juvenile systemic lupus erythematosus
Lupus, August 1, 2007; 16(8): 593 - 599.
[Abstract] [PDF]


Home page
Arch Intern MedHome page
R. F. Spiera, R. S. Berman, A. J. Werner, and H. Spiera
Ticlopidine-Induced Lupus: A Report of 4 Cases
Arch Intern Med, October 28, 2002; 162(19): 2240 - 2243.
[Abstract] [Full Text] [PDF]


Home page
Rheumatology (Oxford)Home page
A. A. Bengtsson, L. Rylander, L. Hagmar, O. Nived, and G. Sturfelt
Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden
Rheumatology, May 1, 2002; 41(5): 563 - 571.
[Abstract] [Full Text] [PDF]


Home page
LupusHome page
S Blomberg, M L Eloranta, B Cederblad, K Nordlind, G L Alm, and L Ronnblom
Presence of cutaneous interferon-a producing cells in patients with systemic lupus erythematosus
Lupus, July 1, 2001; 10(7): 484 - 490.
[Abstract] [PDF]


Home page
LupusHome page
A A Bengtsson, G Sturfelt, L Truedsson, J Blomberg, G Alm, H Vallin, and L Ronnblom
Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies
Lupus, November 1, 2000; 9(9): 664 - 671.
[Abstract] [PDF]


Home page
J. Immunol.Home page
U. Bave, G. V. Alm, and L. Ronnblom
The Combination of Apoptotic U937 Cells and Lupus IgG Is a Potent IFN-{alpha} Inducer
J. Immunol., September 15, 2000; 165(6): 3519 - 3526.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Vallin, A. Perers, G. V. Alm, and L. Ronnblom
Anti-Double-Stranded DNA Antibodies and Immunostimulatory Plasmid DNA in Combination Mimic the Endogenous IFN-{alpha} Inducer in Systemic Lupus Erythematosus
J. Immunol., December 1, 1999; 163(11): 6306 - 6313.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
C. J Hardy, B. P Palmer, K. R Muir, A. J Sutton, and R. J Powell
Smoking history, alcohol consumption, and systemic lupus erythematosus: a case-control study
Ann Rheum Dis, August 1, 1998; 57(8): 451 - 455.
[Abstract] [Full Text]


Home page
LupusHome page
L. E. Adams and A.-B. Mongey
Role of Genetic Factors in Drug-Related Autoimmunity
Lupus, December 1, 1994; 3(6): 443 - 447.
[Abstract] [PDF]


Home page
LupusHome page
L. A. Love
New Environmental Agents Associated With Lupus-Like Disorders
Lupus, December 1, 1994; 3(6): 467 - 471.
[Abstract] [PDF]



Advertisement